Leukemia: Clinical Trials

85 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

85 terminated. 85 Phase 3, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 385Terminated 85
Phase 212Terminated 12

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 85 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive
Phase 3TerminatedSarit Assouline82023-11-012026-05-29
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia
Phase 3TerminatedGilead Sciences3782022-07-072025-04-04
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Entospletinib, Placebo, Cytarabine - Nucleophosmin 1-mutated Acute Myeloid Leukemia
Phase 3TerminatedKronos Bio152021-11-242024-01-10
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Uproleselan, Placebo - Relapsed/Refractory AML
Phase 3TerminatedApollomics Inc.1402021-11-172025-06-27
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia
Phase 2 / Phase 3TerminatedInstitut de Recherches Internationales Servier422021-07-072026-10-29
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia
Phase 3TerminatedGilead Sciences2582021-07-012025-02-05
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Dociparstat, Control - Acute Myeloid Leukemia
Phase 3TerminatedJazz Pharmaceuticals92021-04-302024-04-15
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib - Acute Myeloid Leukemia
Phase 3TerminatedUniversity Hospital Heidelberg282021-04-012022-07-01
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease
Phase 3TerminatedOncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)112021-01-052023-02-08
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Sabatolimab, Azacitidine, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase 3TerminatedNovartis Pharmaceuticals5302020-06-082026-01-13
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
Venetoclax, Azacitidine, Best Supportive Care (BSC) - Acute Myeloid Leukemia (AML), Cancer
Phase 3TerminatedAbbVie4652020-02-262026-06-04
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Dexamethasone, Amsacrine, Cytarabine - Relapsed or Refractory Acute Myeloid Leukemia
Phase 3TerminatedUniversity Hospital, Toulouse732020-01-132025-04-10
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality
Optimal medical treatment, usual clinical practice - Chronic Myeloid Leukemia (CML)
Phase 3TerminatedUniversity Hospital, Angers802019-12-202025-03-17
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
DFP-10917, Cytarabine, Azacitidine - Leukemia, Myeloid, Acute
Phase 3TerminatedDelta-Fly Pharma, Inc.1672019-11-222026-01-22
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Ublituximab, Umbralisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2 / Phase 3TerminatedTG Therapeutics, Inc.2772019-05-162024-04-19
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 2 / Phase 3TerminatedBellicum Pharmaceuticals12018-12-272023-09-29
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia
Phase 3TerminatedCornerstone Pharmaceuticals2002018-11-122023-02-08
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Uproleselan, Placebo - Acute Myeloid Leukemia
Phase 3TerminatedGlycoMimetics Incorporated3882018-10-152024-07-29
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Panobinostat - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
Phase 3TerminatedGoethe University522018-07-242023-02-16
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 3TerminatedKiadis Pharma632017-11-292022-05-24

Showing 20 of 85. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (34)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (17)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (17)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15)  ·  Myelodysplastic Syndromes (14)  ·  Lymphoma (10)  ·  Leukemia, Myeloid, Chronic-Phase (9)  ·  Lymphoma, Follicular (8)  ·  Lymphoma, B-Cell, Marginal Zone (7)  ·  Myeloproliferative Disorders (7)  ·  Leukemia, Myeloid (6)  ·  Graft vs Host Disease (5)  ·  Leukemia, Myelomonocytic, Chronic (5)  ·  Lymphoma, Large B-Cell, Diffuse (5)

Broader conditions

Hemic and Lymphatic Diseases (85)  ·  Neoplasms by Histologic Type (83)  ·  Hematologic Diseases (82)  ·  Neoplasms (80)  ·  Leukemia, Myeloid (48)  ·  Disease Attributes (40)  ·  Pathologic Processes (40)  ·  Pathological Conditions, Signs and Symptoms (40)  ·  Immune System Diseases (38)  ·  Immunoproliferative Disorders (38)  ·  Lymphatic Diseases (38)  ·  Lymphoproliferative Disorders (38)  ·  Chronic Disease (37)  ·  Leukemia, Lymphoid (35)

Interventions

Cytarabine (11)  ·  Cyclophosphamide (10)  ·  Azacitidine (8)  ·  Imatinib Mesylate (7)  ·  Etoposide (6)  ·  fludarabine (6)  ·  idelalisib (6)  ·  nilotinib (6)  ·  Busulfan (5)  ·  Methotrexate (5)  ·  Whole-Body Irradiation (5)  ·  venetoclax (5)  ·  Mitoxantrone (4)  ·  Rituximab (4)  ·  Bendamustine Hydrochloride (3)

Sponsors

Gilead Sciences (8)  ·  Novartis Pharmaceuticals (7)  ·  M.D. Anderson Cancer Center (3)  ·  TG Therapeutics, Inc. (3)  ·  Alliance for Clinical Trials in Oncology (2)  ·  Ariad Pharmaceuticals (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Kiadis Pharma (2)  ·  Masonic Cancer Center, University of Minnesota (2)  ·  Merck Sharp & Dohme LLC (2)  ·  University Hospital Carl Gustav Carus (2)  ·  AbbVie (1)  ·  Acute Leukemia French Association (1)  ·  Amgen (1)  ·  Apollomics Inc. (1)

Countries

United States (56)  ·  France (27)  ·  Germany (27)  ·  Canada (24)  ·  Italy (24)  ·  Spain (24)  ·  Australia (23)  ·  United Kingdom (21)  ·  Belgium (20)  ·  Poland (16)  ·  South Korea (15)  ·  Czechia (14)  ·  Israel (13)  ·  Netherlands (13)  ·  Austria (10)

Top investigators

Andrea Velardi, MD (1)  ·  Benjamin Lichtiger, MD (1)  ·  Ching-Hon Pui, MD (1)  ·  Dan DeAngelo, MD (1)  ·  Daniel J DeAngelo, MD, PhD (1)

Results publications

PMID 37703506, PMID 15226337, PMID 15247354, PMID 18838471, PMID 19270260, PMID 20850381, PMID 21459791, PMID 22315495, PMID 22658895, PMID 22959335, PMID 23248249, PMID 23515925, PMID 23749683, PMID 24472814, PMID 24859364, PMID 25103870, PMID 25882396, PMID 27083332, PMID 28257752, PMID 28380315, PMID 29550384, PMID 30916608, PMID 30995176, PMID 32167393, PMID 32289160, PMID 32599655, PMID 33026184, PMID 33054084, PMID 33542479, PMID 33683917, PMID 34161631, PMID 34699069, PMID 34732236, PMID 35622074, PMID 36757706, PMID 37083373, PMID 40009500, PMID 40227676, PMID 40233321, PMID 40454396, PMID 41074700, PMID 41406403

NIH funding

2015 (3), U10CA031946 (2), 2008 (1), 2014 (1), 2016 (1), 2019 (1), 2023 (1), P30CA036727 (1), P30CA069533 (1), U01HL069294 (1), U24CA076518 (1)